Median Technologies is making significant strides in the fight against lung cancer with its innovative AI-powered software, eyonis® LCS. This Software as a Medical Device (SaMD) is designed to detect and diagnose lung cancer through Low Dose Computed Tomography (LDCT) images, marking a substantial advancement in early cancer detection. The eyonis® LCS has already met the primary endpoints in two pivotal clinical trials, paving the way for its regulatory submissions for FDA 510(k) clearance and CE marking. As a result, it is on track for commercialization by the end of this year, providing a potentially game-changing tool for clinicians and payers alike.

At the forefront of this innovation, Median will present its findings on the economic benefits of eyonis® LCS at the ISPOR 2025 conference, a leading event for health economics and outcomes research. Using a Markov health economic model, the analysis highlights how eyonis® LCS can improve early detection, reduce unnecessary procedures, and lead to significant cost savings for U.S. healthcare payers. This analysis underscores the importance of integrating AI-driven solutions like eyonis® LCS into routine lung cancer screening programs to not only enhance patient outcomes but also reduce the financial burden on healthcare systems. These findings offer crucial insights that could drive broader adoption of AI tools in cancer care.

Median will also present additional data at the American Thoracic Society (ATS) International Conference, showcasing the results from its pivotal REALITY trial. This data demonstrates that eyonis® LCS optimizes the detection, localization, and management of small, screening-detected lung nodules, ultimately leading to earlier diagnoses, more effective treatments, and better survival rates. As a result, eyonis® LCS offers a transformative approach to lung cancer screening, combining advanced AI technology with tangible clinical and economic benefits. With its upcoming regulatory submission and anticipated clearance, eyonis® LCS stands poised to revolutionize lung cancer care, offering both enhanced patient outcomes and significant cost efficiencies.

MedTech Spectrum's Summary

AI-Driven Innovation in Cancer Detection: Median Technologies’ eyonis® LCS is an AI-powered software that enhances early lung cancer detection and diagnosis using LDCT imaging, having met pivotal clinical trial endpoints and advancing toward FDA and CE regulatory approvals.

Economic and Clinical Impact: Data presented at ISPOR 2025 demonstrates that eyonis® LCS improves early detection accuracy, reduces unnecessary procedures, and generates significant cost savings for healthcare payers, supporting its integration into routine screening programs.

Toward Global Adoption: With promising clinical results from the REALITY trial and imminent regulatory submission, eyonis® LCS is positioned to transform lung cancer screening and patient outcomes across international healthcare systems.